{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:55:02Z","timestamp":1791654902405,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacl.2025.12.013","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:16:28Z","timestamp":1765901788000},"page":"279-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3617-4921","authenticated-orcid":false,"given":"Luis E.","family":"Simental-Mend\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Simental-Mend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Jazel","family":"Barrag\u00e1n-Z\u00fa\u00f1iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2582-5766","authenticated-orcid":false,"given":"Paola","family":"Aguill\u00f3n-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.12.013_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-511X-8-19","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults","volume":"8","author":"Detopoulou","year":"2009","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.013_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102953118","article-title":"Lipoprotein-associated phospholipase A2: a paradigm for allosteric regulation by membranes","volume":"119","author":"Mouchlis","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib3","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/s41598-017-16464-5","article-title":"Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"issue":"9725","key":"10.1016\/j.jacl.2025.12.013_bib4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.12.013_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2016.12.006","article-title":"Lipoprotein-associated phospholipase A2 in coronary heart disease: review and meta-analysis","volume":"465","author":"Li","year":"2017","journal-title":"Clin Chim\u00a0Acta"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2025.12.013_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev-pharmtox-051921-090208","article-title":"Pros and cons of long-chain omega-3 polyunsaturated fatty acids in cardiovascular health","volume":"63","author":"Djuricic","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00394-008-0758-z","article-title":"The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults","volume":"48","author":"Weinkouff Pedersen","year":"2009","journal-title":"Eur J Nutr"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00394-010-0126-7","article-title":"Omega-3 fatty acids and lipoprotein associated phospholipase A 2in healthy older adult males and females","volume":"50","author":"Nelson","year":"2011","journal-title":"Eur J Nutr"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.013_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.013_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jacl.2011.09.001","article-title":"Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia","volume":"5","author":"Maki","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.013_bib12","first-page":"148","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"20","author":"Moher","year":"2016","journal-title":"Rev\u00a0Esp\u00a0Nutr\u00a0Hum\u00a0Diet"},{"key":"10.1016\/j.jacl.2025.12.013_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2025.12.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108899","article-title":"Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: a meta-analysis of randomized controlled trials","volume":"177","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.013_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/00325481.2019.1643633","article-title":"Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides","volume":"131","author":"Vijayaraghavan","year":"2019","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jacl.2014.12.001","article-title":"Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia","volume":"9","author":"Skulas-Ray","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.013_bib17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.amjcard.2016.10.027","article-title":"Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials","volume":"119","author":"Mosca","year":"2017","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.013_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2019.05.057","article-title":"Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid\/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study)","volume":"124","author":"Miller","year":"2019","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12952-015-0040-x","article-title":"Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study","volume":"14","author":"Krantz","year":"2015","journal-title":"J Negat Results Biomed"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.013_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11745-014-3968-6","article-title":"n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial","volume":"50","author":"Hedengran","year":"2015","journal-title":"Lipids"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.013_bib22","first-page":"434","article-title":"Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina","volume":"24","author":"Gajos","year":"2014","journal-title":"Nutr\u00a0Metab\u00a0Cardiovasc\u00a0Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-015-0100-8","article-title":"Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial","volume":"14","author":"Dunbar","year":"2015","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2015.10.012","article-title":"Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2025.12.013_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2025.12.013_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/med.21597","article-title":"Lipoprotein-associated phospholipase A2: the story continues","volume":"40","author":"Huang","year":"2020","journal-title":"Med Res Rev"},{"issue":"12","key":"10.1016\/j.jacl.2025.12.013_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21124501","article-title":"An updated review of pro-and anti-inflammatory properties of plasma lysophosphatidylcholines in the vascular system","volume":"21","author":"Knuplez","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jacl.2025.12.013_bib30","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.3390\/nu13103384","article-title":"N-3 polyunsaturated fatty acids and their lipid mediators as a potential immune\u2013nutritional intervention: a molecular and clinical view in hepatic disease and other non-communicable illnesses","volume":"13","author":"Vielma","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jacl.2025.12.013_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2019.11.014","article-title":"Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: a phase 4, randomized study","volume":"292","author":"Masuda","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2025.12.013_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2009.05.029","article-title":"Metabolism and atherogenic disease association of lysophosphatidylcholine","volume":"208","author":"Schmitz","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.013_bib33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/00325481.2021.1921491","article-title":"EPA\u2019s pleiotropic mechanisms of action: a narrative review","volume":"133","author":"Nelson","year":"2021","journal-title":"Postgrad Med"},{"issue":"7","key":"10.1016\/j.jacl.2025.12.013_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029109","article-title":"Comparative effects of mineral oil, corn oil, eicosapentaenoic acid, and docosahexaenoic acid in an in vitro atherosclerosis model","volume":"12","author":"Sherratt","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"suppl J","key":"10.1016\/j.jacl.2025.12.013_bib35","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2025.12.013_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.jacl.2025.12.013_bib38","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/eurjpc\/zwae003","article-title":"Omega-3 fatty acids for cardiovascular event lowering","volume":"31","author":"Kaur","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2025.12.013_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jacl.2022.05.067","article-title":"Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: a review of key findings from REDUCE-IT","volume":"16","author":"Gaba","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.013_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpdd.84","article-title":"Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects","volume":"3","author":"Braeckman","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"suppl J","key":"10.1016\/j.jacl.2025.12.013_bib41","first-page":"J3","article-title":"Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites","volume":"22","author":"O\u2019Connell","year":"2020","journal-title":"Eur\u00a0Heart J\u00a0Suppl"},{"key":"10.1016\/j.jacl.2025.12.013_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2019.01129","volume":"10","author":"Stupin","year":"2019","journal-title":"Front Physiol"},{"issue":"9","key":"10.1016\/j.jacl.2025.12.013_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/biomedicines8090306","article-title":"The anti-inflammatory and antioxidant properties of n-3 PUFAs: their role in cardiovascular protection","volume":"8","author":"Oppedisano","year":"2020","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.013_bib44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/ijms24021353","article-title":"The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles","volume":"24","author":"Khan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2025.12.013_bib45","first-page":"563","article-title":"The association of PLA2G7 gene polymorphisms with serum Lp-PLA2 activity and lipid profile in Han Chinese patients with coronary heart disease","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmacogenomics\u00a0Pers\u00a0Med"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.013_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003407","article-title":"Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease","volume":"5","author":"Wallentin","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jacl.2025.12.013_bib47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O\u2019Donoghue","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2025.12.013_bib48","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.ATV.0000240406.89440.0c","article-title":"Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community","volume":"26","author":"Gerber","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.jacl.2025.12.013_bib49","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1161\/01.CIR.0000143377.53389.C8","article-title":"Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany","volume":"110","author":"Koenig","year":"2004","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2025.12.013_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/nutrit\/nuac101","volume":"81","author":"Calder\u00f3n-P\u00e9rez","year":"2023","journal-title":"Nutr Rev"},{"issue":"6","key":"10.1016\/j.jacl.2025.12.013_bib51","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10557-024-07634-5","article-title":"Effect of statin treatment on lipoprotein-associated phospholipase A2 mass and activity: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"39","author":"Sahebkar","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.jacl.2025.12.013_bib52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0003319710375089","article-title":"In vitro and in vivo effects of statins on platelet-activating factor and its metabolism","volume":"62","author":"Tsantila","year":"2011","journal-title":"Angiology"},{"issue":"15","key":"10.1016\/j.jacl.2025.12.013_bib53","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/0113816128345231240925095400","article-title":"Effect of fibrates on lipoprotein-associated phospholipase A2 mass and activity: a systematic review and meta-analysis of controlled clinical trials","volume":"31","author":"Simental-Mendia","year":"2025","journal-title":"Curr Pharm Des"},{"issue":"10","key":"10.1016\/j.jacl.2025.12.013_bib54","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1194\/jlr.D300021-JLR200","article-title":"Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus","volume":"44","author":"Kujiraoka","year":"2003","journal-title":"J Lipid Res"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:27:52Z","timestamp":1772368072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1933287425005446"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}